Optimizing Clinical Outcomes in Blood Cancers through Groundbreaking Translational Research
March 27, 2020
Virtual Lecture
3.75 CME credit available until: March 26, 2021
Estimated Time to Complete Activities: 30 minutes for Module 1; 45 minutes for Modules 2 & 3; 30 minutes for Module 4; 75 minutes for Module 5
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Activity Purpose
This activity will provide learners with the latest developments in translational medicine for leukemia, lymphoma, and myeloma and how these developments can be incorporated into regimens to improve the outcome of patients with these diseases.
Learning Objectives
After completing this activity, participants should be better able to:
- Describe the latest advances in translational medicine for patients with acute myeloid leukemia (AML), multiple myeloma, lymphoma, and pediatric leukemia
- Explain how novel genetic screening strategies currently in development may be used to identify patients at risk of developing hematologic malignancies and direct early intervention strategies
- Select the most appropriate treatment among current and emerging options for patients with hematologic malignancies
- Identify novel treatment strategies that may improve patient quality of life by reducing toxicity of treatment and prolonging disease control
Faculty
Cheryl L. Willman, MD (Chair)
The Maurice and Marguerite Liberman Distinguished Endowed Chair in Cancer Research
UNM Distinguished Professor of Pathology, UNM School of Medicine
Director & CEO, University of New Mexico Comprehensive Cancer Center
Albuquerque, NM
Philippe Armand, MD, PhD
Harold and Virginia Lash/David Lash Chair in Lymphoma Research
Chief, Lymphoma Division
Dana-Farber Cancer Institute
Boston, MA
Catherine Bollard, MD, FRACP, FRCPA
Bosworth Chair for Cancer Biology
Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine
Director, Center for Cancer and Immunology Research
Director, Program for Cell Enhancement and Technologies for Immunotherapy
Children’s National Health System
The George Washington University, School of Medicine and Health Sciences
Washington, DC
Benjamin L. Ebert, MD, PhD
George P. Canellos, MD and Jean S. Canellos Professor of Medicine
Harvard Medical School
Chair, Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Investigator, Howard Hughes Medical Institute
Stephen P. Hunger, MD
Chief, Division of Oncology
Director, Center for Childhood Cancer Research
Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics
Children’s Hospital of Philadelphia
Professor, Department of Pediatrics
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
C. Ola Landgren, MD, PhD
Professor of Medicine
Chief, Myeloma Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Sponsors and Supporters
This activity is jointly provided by The Leukemia & Lymphoma Society, RMEI Medical Education, LLC, and Postgraduate Institute for Medicine.
The educational portion of this activity is supported by independent educational grants from Amgen Inc., AstraZeneca Pharmaceuticals LP, and Bristol-Myers Squibb Company. Additional funding provided by The Leukemia & Lymphoma Society.